Lessons learned from implementing Clostridium difficile–focused antibiotic stewardship interventions

Infection Control and Hospital Epidemiology

Volumn 35, Issue , 2014, Pages S86-S95

  Ostrowsky, B ^a,b   Ruiz, R ^c   Brown, S ^a   Chung, P ^a,b   Koppelman, E ^d   van Deusen Lukas, C ^d   Guo, Y ^a,b   Jalon, H ^e   Sumer, Z ^c   Araujo, C ^c   Sirtalan, I ^c   Brown, C ^a,b   Riska, P ^a,b   Currie, B ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e United Hospital Fund New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CIPROFLOXACIN; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC STEWARDSHIP INTERVENTION; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG USE; ENVIRONMENTAL SANITATION; HEALTH CARE FACILITY; HEALTH PROGRAM; HOSPITAL; HUMAN; INFECTION CONTROL; INFORMATION PROCESSING; PRESCRIPTION; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CONTROLLED BEFORE-AFTER STUDIES; CROSS INFECTION; DRUG UTILIZATION REVIEW; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 84907982335     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1086/677828     Document Type: Article

References (27)

1. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections. Atlanta: Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf.
2. Malpiedi PJ, Peterson KD, Soe MM, et al. 2011 National and State Healthcare-Associated Infection Standardized Infection Ratio Report. Atlanta: Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/hai/national-annual-sir/index.html.
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 2006;12:409–415.
4. Elixhauser A, Jhung MA. Clostridium difficile–associated Diseases in U.S. Hospitals, 1993–2005. Healthcare Cost and Utilization Project statistical brief 50. Rockville, MD: Agency for Healthcare Research and Quality, 2008. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb50.jsp.
5. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55(S2): S65–S70.
6. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile–related mortality rates, United States, 1999–2004. Emerg Infect Dis 2007;13:1417–1419.
7. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013;173:1359–1367.
8. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–455.
9. Dellit T, Owen R, McGowan J, Gerding D, Weinstein J, Burke J. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.
10. Moody J, Cosgrove S, Olmstead R, et al. Antimicrobial stewardship: a collaborative partnership between infection preventionists and healthcare epidemiologists. Infect Control Hosp Epidemiol 2012;33(4):328–330.
11. Koll B, Ruiz R, Calfee B, et al. Prevention of hospital-onset Clostridium difficile infection in the New York metropolitan region using a collaborative intervention model. J Healthc Qual 2014;36:35–45.
12. Agency for Healthcare Research and Quality (AHRQ). Toolkit for Reduction of Clostridium difficile Infections Through Antimicrobial Stewardship: The Evaluation and Research on Antimicrobial Stewardship’s Effect on Clostridium difficile (ERASE C. difficile) Project. Rockville, MD: AHRQ, 2012. http://www.ahrq.gov/qual/cdifftoolkit/cdiffl1qu.htm.
13. Chung P, Guo Y, Ostrowsky B. Does choice of control group affect the association of antibiotics with Clostridium difficile-associated diarrhea? In: SHEA 2011 Annual Scientific Meeting; April 1–4, 2011; Dallas, TX. http://shea.confex.com/shea/2011/webprogram/Paper4443.html.
14. McDonald L, Coignard B, Dubberke E, Song X, Horan T, Kutty P. Ad hoc Clostridium difficile surveillance working group recommendations for surveillance C. difficile–associated disease. Infect Control Hosp Epidemiol 2007;28:140–145.
15. Gase K, Haley V, Xiong K, Van Antwerpen C, Stricof R. Comparison of two Clostridium difficile surveillance methods: National Healthcare Safety Network’s laboratory-identified event reporting module versus clinical surveillance. Infect Control Hosp Epidemiol 2013;34(3):284–290.
16. Centers for Disease Control and Prevention (CDC), National Healthcare Safety Network. MDRO-CDAD Module. Atlanta: CDC, 2008. http://www.cdc.gov/nhsn/PDFs/MDRO_CDADprotocolv41Dec08final.pdf.
17. World Health Organization (WHO). Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/ DDD). Geneva: WHO, 2014. http://www.who.int/classifications/atcddd/en/.
18. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 U.S. hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007;44(5):664–670.
19. StataCorp. Stata Statistical Software: Release 11.2. College Station, TX: StataCorp, 2009.
20. Centers for Medicare and Medicaid Services (CMS). Healthcare Cost Report Information System. Baltimore, MD: CMS, 2009. http://www.resdac.org/cms-data/files/hcris.
21. New York State Department of Health. Hospital Profiles Report. Albany, NY: New York State Department of Health, 2013. http://www.health.ny.gov/facilities/hospital/.
22. Brown C, Guo Y, Chung P, Brown S, Ostrowsky B. Feasibility and acceptability of an audit and feedback method of antibiotic stewardship: a pilot study. In: Annual Infectious Diseases Society of America meeting; October 2011; Boston, MA. Poster 31615.
23. VanDeusen Lukas C, Koppelman E, Ostrowsky B, et al. Developing the Capacity to Implement Antimicrobial Stewardship: Opportunities for the Future. Rockville, MD: Agency for Healthcare Research and Quality, 2013. Publication 14-0003.
24. New York State Department of Health. Public Health Law Section 2819: Hospital-Acquired Infection Reporting. Albany, NY: New York State Department of Health, 2009. http://www.health.ny.gov/regulations/public_health_law/section/2819/.
25. New York State Department of Health. Hospital-Acquired Infection (HAI) Rates in New York State Hospitals. Albany, NY: New York State Department of Health, 2013. http://www.health.ny.gov/statistics/facilities/hospital/hospital_acquired_infections/.
26. US Department of Health and Human Services and Centers for Medicare and Medicaid Services. Adoption of NHSN C. diff into FY 2017 Hospital-Acquired Condition Reduction Program. Federal Register, August 19, 2013:50717.
27. US Department of Health and Human Services and Centers for Medicare and Medicaid Services. CMS Intent to Propose Inclusion of NHSN C. diff into FY 2017 Value-Based Purchasing Program in FY 2015 Inpatient Prospective Payment System Proposed Rule. Federal Register, August 19, 2013:50717.